Welcome to our dedicated page for Shoulder Innovations SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Shoulder Innovations, Inc. (NYSE: SI) provide detailed regulatory information about the company’s operations as a commercial-stage medical technology business focused on shoulder surgical care. These documents include current reports on Form 8-K that describe material events such as quarterly financial results and key corporate announcements.
Recent Forms 8-K furnished by Shoulder Innovations cover financial results for quarters ended June 30 and September 30, 2025. In these filings, the company provides net revenue, gross margin, operating loss, net loss and related financial data, along with discussions of factors affecting performance. The filings also reference non-GAAP measures such as Adjusted EBITDA and explain how these metrics are calculated and their limitations.
Other 8-K filings document significant corporate developments. For example, the company has furnished press releases announcing its initial public offering and convertible notes financing, as well as a strategic partnership with Interventional Systems to introduce a shoulder-specific micro-robotic solution that is expected to integrate with the ProVoyance platform. These filings help investors track how Shoulder Innovations is expanding its ecosystem of advanced implant systems, enabling technologies and instrument systems for shoulder arthroplasty.
On Stock Titan’s SEC filings page, users can access these reports as they are made available through the EDGAR system. AI-powered tools can assist in summarizing lengthy filings, highlighting items such as revenue trends, operating results, non-GAAP reconciliations and descriptions of material agreements or partnerships. Users can also review filing exhibits, including earnings press releases and, where provided, conference call transcripts furnished as exhibits to Form 8-K.
Together, the SEC filings for SI offer a structured view of Shoulder Innovations’ financial reporting, regulatory disclosures and significant events related to its focus on the shoulder surgical care market.
SHOULDER INNOVATIONS, INC. director Andrew Hykes filed an initial Form 3 to report his beneficial ownership as a company insider. The filing lists him as a director and does not show any share purchases, sales, or other transactions in this excerpt.
Shoulder Innovations, Inc. reported that on February 26, 2026, Geoff Pardo resigned as a Class I director, a member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee, effective immediately. The company stated his resignation was not due to any disagreement with management or the Board.
On the same date, the Board appointed Andrew (Drew) Hykes, age 53, as a Class I director and member of the Compensation Committee, also effective immediately. He will receive standard non-employee director compensation and enter into the company’s standard indemnification agreement. The Board determined he is an independent director and meets New York Stock Exchange and Exchange Act requirements for Compensation Committee service.
The filing and accompanying press release highlight Mr. Hykes’s more than 25 years of medical device and healthcare experience, including leadership roles at Okami Medical, Inari Medical, Sequent Medical, and Medtronic, as well as his banking background and business degrees from the University of Wisconsin–Madison and Harvard Business School.
Shoulder Innovations, Inc. CEO and Executive Chairman Robert Joseph Ball reported exercising stock options for common stock on February 6, 2026. He acquired 10,000 shares at $2.4804 per share and 2,062 shares at $2.0988 per share through option exercises coded “M.”
After these transactions, Ball directly beneficially owned 276,666 shares of common stock. His option holdings included 319,756 and 181,376 stock options remaining after the exercises. Footnotes note that his holdings include over 140,000 shares previously received without consideration as in‑kind distributions from several investment funds.
Shoulder Innovations, Inc.
The option is held directly and vests in four equal annual installments, with one-fourth of the underlying shares vesting on March 1 each year, beginning March 1, 2027. After this grant, Points beneficially owns 126,357 stock options tied to common shares.
Shoulder Innovations, Inc. reported that officer David Lawrence Blue received a grant of stock options on January 30, 2026. The award covers 88,450 options for common stock at an exercise price of $14.16 per share, all held as a direct ownership position.
The options vest in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning March 1, 2027, until fully vested. After this grant, Blue beneficially owns 88,450 derivative securities in the form of these stock options.
Shoulder Innovations, Inc. granted stock options to its CEO and Executive Chairman, Robert Joseph Ball. On January 30, 2026, he received a stock option covering 265,351 shares of common stock at an exercise price of $14.16 per share.
The option was granted directly to him and is scheduled to vest in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning on March 1, 2027, which spreads the potential ownership benefit over several years.
Shoulder Innovations, Inc. disclosed a new stock option grant to Chief Operating Officer and director Matthew Fraser Ahearn. On January 30, 2026, he received an option covering 88,450 shares of common stock at an exercise price of $14.16 per share.
According to the vesting terms, the option vests in four equal annual installments. One-fourth of the underlying shares will vest on March 1 each year, beginning on March 1, 2027, aligning the award with multi-year executive retention and performance incentives.
Shoulder Innovations, Inc. Chief Financial Officer Jeffrey S. Points reported acquiring common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,076 shares of common stock at a purchase price of $12.16 per share, which the plan set at 85% of the closing price of the stock on that date. Following this transaction, he beneficially owned 55,521 common shares directly, and an additional 50 shares indirectly held by his son.
Shoulder Innovations, Inc. officer David Lawrence Blue reported buying common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,041 shares of common stock at $12.16 per share, a price set at 85% of the closing price that day under the ESPP rules. After this transaction, he beneficially owned 139,372 shares, held directly. Blue serves as the company’s Chief Customer Experience Officer, and the filing notes that this is a voluntary report of the ESPP purchase.
Shoulder Innovations, Inc. CEO & Executive Chairman Robert Joseph Ball reported acquiring additional common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,661 shares of common stock at a purchase price of $12.16 per share, which the plan set at 85% of the closing price of the company’s common stock on that date. Following this ESPP purchase, Ball beneficially owned 120,118 shares of Shoulder Innovations common stock held directly.